↑ 疾患リストへ ← 戻る

 98. 好酸球性消化管疾患 [臨床試験数:78,薬物数:85(DrugBank:33),標的遺伝子数:31,標的パスウェイ数:26] 

Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03678545May 202030 September 2019Dupilumab in Eosinophilic GastritisA Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic GastritisEosinophilic Gastritis;Eosinophilic GastroenteritisDrug: Dupilumab (blinded);Drug: Placebo (blinded);Drug: Dupilumab (open-label)Children's Hospital Medical Center, CincinnatiRegeneron PharmaceuticalsNot recruiting18 Years70 YearsAll40Phase 2United States
2NCT02873468February 202014 October 2019Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic EsophagitisRandomized, Double-blind, Multicentric, Parallel, National, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Florence 30 µg/mL;Drug: Florence 60 µg/mL;Drug: Florence 90 µg/mL;Other: PlaceboEMSNot recruiting18 YearsN/AAll116Phase 2
3NCT04149470December 201911 November 2019Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)Eosinophilic EsophagitisDrug: Omeprazole 20mg BIDUniversity of Colorado, DenverChildren's Hospital ColoradoNot recruiting8 Years22 YearsAll90Phase 4
4NCT03615950October 1, 201922 July 2019Effects of Swallowed Steroids on Bone Density and Growth in Pediatric Eosinophilic EsophagitisEffects of Swallowed Corticosteroids on Bone Mineral Density and Growth Velocity in Children With Eosinophilic EsophagitisEosinophilic EsophagitisDiagnostic Test: Bone Mineral Density (DEXA) scan;Diagnostic Test: Vitamin D Measurement;Diagnostic Test: Height measurement;Other: Assessment of medication complianceArkansas Children's Hospital Research InstituteUniversity of ArkansasRecruiting5 Years12 YearsAll60Phase 3United States
5NCT03656380March 20, 201914 October 2019Mepo for EoE StudyA Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant SymptomsEoE;Eosinophilic EsophagitisDrug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: PlaceboUniversity of North Carolina, Chapel HillGlaxoSmithKline;University of Utah;Northwestern University;Minnesota Gastroenterology, P.A.Recruiting16 Years75 YearsAll72Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03664960November 14, 20184 March 2019An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisA Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisEosinophilic Gastritis;Eosinophilic GastroenteritisDrug: AK002Allakos, Inc.Recruiting18 Years80 YearsAll60Phase 2United States
7NCT03633617September 24, 20184 November 2019Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)Eosinophilic EsophagitisDrug: Dupilumab;Drug: PlaceboRegeneron PharmaceuticalsSanofiRecruiting12 YearsN/AAll425Phase 3United States;Australia;Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom
8NCT03496571July 18, 201826 August 2019A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisA Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisEosinophilic Gastritis;Eosinophilic GastroenteritisDrug: AK002;Other: PlaceboAllakos, Inc.Not recruiting18 Years80 YearsAll65Phase 2United States
9NCT03245840October 5, 20174 November 2019Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)Eosinophilic Esophagitis (EoE)Drug: Budesonide oral suspensionShireRecruiting11 Years55 YearsAll100Phase 3United States
10NCT03191864June 30, 201718 December 2018Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: APT-1011;Drug: PlaceboAdare Pharmaceuticals, Inc.Not recruiting18 Years75 YearsAll100Phase 2United States;Belgium;Canada;Germany;Spain;Switzerland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03290482June 19, 201726 August 2019Natural History of Eosinophilic EsophagitisNatural History of Eosinophilic Esophagitis: A Longitudinal Follow-up Over 10 YearsEosinophilic EsophagitisDiagnostic Test: Barium Esophagram;Device: EsophaCap;Diagnostic Test: Physical Examination and QuestionnairesMayo ClinicRecruiting18 YearsN/AAll65N/AUnited States
12NCT03029091January 19, 201720 May 2019An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue DisorderEosinophilic EsophagitisDrug: Losartan PotassiumChildren's Hospital Medical Center, CincinnatiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS)Not recruiting5 Years25 YearsAll15Phase 2United States
13EUCTR2017-003737-29-NL30 April 2019Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receives medication without active substance), phase II/III study on the efficacy and tolerability of oral budesonide suspension in comparison with placebo in children and adolescents with eosinophilic esophagitisDouble-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophilic esophagitis - Budesonide oral suspension vs. placebo in pediatric eosinophilic esophagitisActive eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis
MedDRA version: 20.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Budesonide oral suspension [0.2 mg/ml]
Pharmaceutical Form: Oral suspension
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 0.2-
Pharmaceutical form of the placebo: Oral suspension
Route of administration of the placebo: Oral use
Dr. Falk Pharma GmbHNot Available Female: yes
Male: yes
75Phase 2;Phase 3Portugal;Greece;Spain;Israel;Germany;Netherlands;United Kingdom
14NCT04069429July 201622 October 2019Radiation Dose in Humans From Orally Administered Tc99m-HeparinRadiation Dose in Humans From Orally Administered Tc99m-HeparinEosinophilic EsophagitisRadiation: Computerized Tomography scan;Radiation: Single Photon Emission Computed Tomography scans;Drug: Technetium Tc 99M;Radiation: Planar Images;Procedure: EsophagogastroduodenoscopyUniversity of UtahRecruiting18 Years70 YearsAll17Early Phase 1United States
15NCT02778867May 20, 201630 September 2019SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet StudySix Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid TrialEosinophilic Gastrointestinal Disorders (EGIDs);Eosinophilic Esophagitis (EoE)Drug: Flovent;Other: elimination diet therapyChildren's Hospital Medical Center, CincinnatiOffice of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID)Not recruiting18 Years60 YearsAll130Phase 2/Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02736409April 29, 20166 May 2019An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)Eosinophilic Esophagitis (EoE)Drug: Oral Budesonide Suspension (OBS);Drug: PlaceboShireNot recruiting11 Years55 YearsAll200Phase 3United States;United Kingdom
17JPRN-UMIN0000210412016/02/1510 September 2019A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitisA study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis - A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitisEosinophilic esophagitisadministration of Vonoprazan (20mg/day for 2 months)Second department of Internal Medicine, Shimane University Faculty of MedicineNot Recruiting20years-oldNot applicableMale and Female5Not selectedJapan
18NCT02493335January 15, 201625 February 2019Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic EsophagitisDouble-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Budesonide 0.5mg orodispersible tablet twice daily;Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice dailyDr. Falk Pharma GmbHNot recruiting18 Years75 YearsAll204Phase 3Germany
19NCT02610816January 201620 June 2016Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed GlucocorticoidsEosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed GlucocorticoidsEosinophilic Esophagitis;Eosinophilic Gastrointestinal Disorders (EGIDs),Other: elimination diet therapy;Drug: Flovent (fluticasone propionate)Children's Hospital Medical Center, CincinnatiCollaborator: Patient Centered Outcome Research Institute (PCORI)Recruiting6 Years17 YearsBoth292Phase 2/Phase 3United States
20EUCTR2014-001485-99-DE08/12/201530 April 2019Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets in comparison with placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitisDouble-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis - Maintenance of remission with budesonide effervescent tabl. vs. placebo in eosinophilic esophagitisMaintenance of remission in eosinophilic esophagitis
MedDRA version: 20.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: 1 mg budesonide effervescent tablet for orodispersible use
Product Code: BUET 1mg
Pharmaceutical Form: Effervescent tablet
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Effervescent tablet
Route of administration of the placebo: Oral use
Product Name: 0.5 mg budesonide effervescent tablet for orodispersible use
Product Code: BUET 0.5 mg
Pharmaceutical Form: Effervescent tablet
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Effervescent tablet
Route of administration of the placebo: Oral use
Dr. Falk Pharma GmbHAuthorised Female: yes
Male: yes
204Phase 3Belgium;Spain;Denmark;Netherlands;Germany;United Kingdom;Switzerland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT02605837December 7, 201526 August 2019A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is AchievedOral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled StudyEosinophilic Esophagitis (EoE)Drug: Oral Budesonide Suspension (OBS);Drug: PlaceboShireNot recruiting11 Years55 YearsAll420Phase 3United States
22NCT02579876October 201515 July 2019Milk Patch for Eosinophilic EsophagitisA Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in ChildrenEosinophilic Esophagitis;Milk AllergyDrug: Viaskin Milk 500 mcg;Drug: Viaskin PlaceboChildren's Hospital of PhiladelphiaDBV TechnologiesNot recruiting4 Years17 YearsAll20Phase 2United States
23EUCTR2014-001484-12-DE22/09/20159 January 2017Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (tested against tablets without active substance), phase III study on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathological remission in adult patients with active eosinophilic esophagitisDouble-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis - Induction of remission with budesonide effervescent tablets vs. placebo in eosinophilic esophagitisActive eosinophilic esophagitis
MedDRA version: 19.0 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: 1 mg budesonide effervescent tablet for orodispersible use
Product Code: BUET 1mg
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Oral use
Dr. Falk Pharma GmbHNot RecruitingFemale: yes
Male: yes
90Phase 3Spain;Belgium;Netherlands;Germany;Switzerland
24NCT02379052June 3, 201526 February 2018Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE)A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Dupilumab;Drug: PlaceboRegeneron PharmaceuticalsSanofiNot recruiting18 Years65 YearsAll47Phase 2United States
25NCT02434705April 201526 August 2019Food Antigen in Eosinophilic EsophagitisProtocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic EsophagitisEosinophilic EsophagitisOther: Antigen (wheat base soy sauce) sprayMayo ClinicRecruiting18 Years80 YearsAll20N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT02019758January 1, 20153 September 2018Budesonide Versus Fluticasone for Treatment of Eosinophilic EsophagitisBudesonide Versus Fluticasone for Treatment of Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Oral Viscous Budesonide;Drug: Fluticasone MDI;Drug: Placebo slurry;Drug: Placebo inhalerUniversity of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting16 Years80 YearsAll173Phase 4United States
27NCT02353078January 201516 December 2017The Effect of Sucralfate Slurry in Patients With Eosinophilic EsophagitisThe Effect of Sucralfate Slurry on Dilated Intercellular Spaces, Tight Junctions, Mucosal Impedance and Mucosal Activity in Patients With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Sucralfate;Procedure: Intraluminal Impedance;Device: Intraluminal ImpedanceMayo ClinicNot recruiting18 Years80 YearsAll3Early Phase 1United States
28NCT02371941December 201411 June 2018Oral Cromolyn Sodium for the Treatment of Eosinophilic EsophagitisA Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic EsophagitisEosinophilic EsophagitisDrug: oral cromolyn sodium;Drug: PlaceboUniversity of TennesseeNot recruiting2 Years18 YearsAll16Phase 4United States
29NCT02314455September 20148 August 2016Esophageal Absorption in EoEEsophageal Absorption in Eosinophilic EsophagitisEosinophilic EsophagitisOther: D-xyloseMayo ClinicNot recruiting18 Years80 YearsBoth14N/AUnited States
30NCT02098473August 31, 201416 December 2017Dose Ranging Study of RPC4046 in Eosinophilic EsophagitisA Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: RPC4046;Drug: PlaceboCelgeneNot recruiting18 Years65 YearsAll100Phase 2United States;Canada;Switzerland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT02058537February 201419 October 2017Bethanechol for Eosinophilic EsophagitisBethanechol for Treatment of Eosinophilic Esophagitis (EoE)Eosinophilic Esophagitis (EoE)Drug: BethanecholUniversity of IowaNot recruiting18 Years75 YearsAll2Phase 2United States
32NCT02125851January 201419 February 2015Comparison of Esophageal Clearance Times of Oral Budesonide PreparationsComparison of Esophageal Clearance Times of Oral Budesonide PreparationsEosinophilic EsophagitisOther: Xanthan Gum;Other: HoneyWalter Reed National Military Medical CenterNot recruiting18 Years75 YearsBoth24N/AUnited States
33EUCTR2014-002465-30-IT2 October 2017Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis.Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis.Eosinophilic Esophagitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Name: Budesonide
Product Code: Budesonide
Pharmaceutical Form: Oral suspension
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 0.19-0.21
Dip. Pediatria UOC Gastroenterologia ed Epatologia PediatricaNot AvailableFemale: yes
Male: yes
Phase 2Italy
34EUCTR2012-005842-39-SE20/12/20131 October 2018Treatment of patients with eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II studyTreatment of eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study for evaluation of treatment effect on group level including symtom questionnairesEosinphilic Esophagitis;Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]Trade Name: Nasonex
Pharmaceutical Form: Oromucosal spray
Pharmaceutical form of the placebo: Suspension and solution for spray
Route of administration of the placebo: Oromucosal use
NU-sjukvården, Norra Älvsborgs LänssjukhusNot RecruitingFemale: yes
Male: yes
60Phase 2Sweden
35NCT01929824August 201314 October 2019Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)A Pilot Study: Nasal Nitric Oxide Levels in Eosinophilic Esophagitis.Eosinophilic EsophagitisOther: Oral Nitric Oxide testingMayo ClinicNot recruiting18 YearsN/AAll50Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01821898July 9, 201320 August 2018Eosinophilic Esophagitis Clinical Therapy Comparison TrialEosinophilic Esophagitis Clinical Therapy Comparison TrialEosinophilic EsophagitisDrug: Oral Budesonide;Other: Elimination dietBaylor College of MedicineNot recruiting3 Years17 YearsAll60Phase 2United States
37NCT01808196April 20135 February 2018Testing Effectiveness of Losartan in Patients With EoE With or Without a CTDA Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.Eosinophilic Esophagitis;Connective Tissue DisordersDrug: Losartan PotassiumChildren's Hospital Medical Center, CincinnatiNot recruiting5 Years21 YearsAll6Phase 2United States
38NCT01814059March 7, 201316 July 2018Sirolimus for Eosinophil-Associated Gastrointestinal DisordersA Phase 1, Open-Label Study of Sirolimus in Eosinophil-Associated Gastrointestinal DisordersEosinophilic Gastroenteritis;Eosinophilic EsophagitisDrug: sirolimusNational Institute of Allergy and Infectious Diseases (NIAID)Not recruiting18 Years65 YearsAll4Phase 1United States
39NCT01865825March 201316 December 2017Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?Erosive EsophagitisRadiation: Esophageal Barium XrayMayo ClinicNot recruiting18 YearsN/AAll20N/AUnited States
40NCT01846962November 201211 June 2018Dietetic Versus Topical Steroids for Pediatric Eosinophilic EsophagitisCOMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS)Eosinophilic EsophagitisDrug: Budesonide;Drug: Fluticasone;Behavioral: six-foods elimination diet;Drug: Oral Viscous Budesonide (OVB)Azienda Policlinico Umberto INot recruiting6 Months18 YearsAll64Phase 4Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT01685034October 201229 August 2016Allergy Immunotherapy in the Management of Eosinophilic EsophagitisEvaluation of the Clinical, Endoscopic and Histologic Effects of Environmental Allergy Immunotherapy in the Treatment of Eosinophilic EsophagitisEosinophilic EsophagitisBiological: Allergy immunotherapy (allergy shots)United States Naval Medical Center, San DiegoNot recruiting18 YearsN/ABoth0N/A
42NCT01642212July 201219 October 2017OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label ExtensionOral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label ExtensionEosinophilic EsophagitisDrug: Oral Budesonide Suspension (MB-9);Drug: PlaceboShireNot recruiting11 Years40 YearsAll93Phase 2United States
43NCT01479231March 201219 February 2015Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic EsophagitisPredictors of PPI Response in Eosinophilic EsophagitisGastroesophageal Reflux Disease;Eosinophilic Esophagitis;DysphagiaDrug: dexlansoprazoleMayo ClinicNot recruiting18 Years80 YearsBoth0Phase 1/Phase 2United States
44EUCTR2009-016692-29-BE20/02/201221 August 2017A study to investigate the efficacy and tolerance of budesonide tablets and suspension in patients suffering from esophagitis over a 14 day periodDouble-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspension vs. placebo in patients with eosinophilic esophagitis - Budesonide effervescent tablets vs. viscous budesonide suspension vs. placebo in EEActive eosinophilic esophagitis
MedDRA version: 14.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: 1mg budesonide effervescent tablet for orodispersible use
Product Code: BUET 1mg
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Current Sponsor code: BUET 1 mg
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Oral use
Product Name: 2mg budesonide effervescent tablet for orodispersible use
Product Code: BUET 2mg
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Current Sponsor code: BUET 2 mg
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Oral use
Product Name: Budesonide [0.4mg/ml] viscous suspension
Product Code: BUU 0.4mg/ml
Pharmaceutical Form: Oral suspension
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Current Sponsor code: BUU: Budesonide viscous suspension
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 0.4-
Pharmaceutical form of the placebo: Oral suspension
Route of administration of the placebo: Oral use
Dr. Falk Pharma GmbHNot RecruitingFemale: yes
Male: yes
100Phase 2Belgium;Germany;Switzerland
45NCT01498497January 201216 December 2017A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects]Eosinophilic EsophagitisDrug: EUR-1100;Drug: PlaceboForest LaboratoriesNot recruiting12 Years55 YearsAll14N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01702701January 20129 September 2019Eosinophilic Esophagitis Treatment: Montelukast vs FluticasoneEosinophilic Esophagitis Treatment: Montelukast vs FluticasoneEosinophilic Esophagitis;DysphagiaDrug: Montelukast;Drug: FluticasoneMedical College of WisconsinNot recruiting18 YearsN/AAll0Phase 3United States
47NCT01458418December 20112 March 2015A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in ChildrenA Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in ChildrenEosinophilic EsophagitisDrug: Montelukast;Other: placebo;Drug: 5 mg MontelukastChildren's Mercy Hospital Kansas CityNot recruiting2 Years17 YearsBoth4N/AUnited States
48NCT01386112September 201119 February 2015Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic EsophagitisA Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE)Eosinophilic EsophagitisDrug: EUR-1100;Drug: placeboAptalis PharmaNot recruiting12 Years55 YearsBoth24Phase 1/Phase 2United States
49NCT01624129January 201119 February 2015New Serological Markers for Eosinophilic EsophagitisEosinophilic EsophagitisDrug: FluticasoneTechnische Universität MünchenRecruiting18 Years80 YearsBoth20N/AGermany
50NCT01056783August 201019 February 2015Proof of Concept Study of OC000459 in Eosinophilic EsophagitisA Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic EsophagitisEosinophilic EsophagitisDrug: OC000459;Drug: PlaceboOxagen LtdNot recruiting18 Years75 YearsBoth26Phase 2Switzerland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT01170234August 201023 April 2019Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic EsophagitisExhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic EsophagitisEosinophilic EsophagitisDevice: NIOX MINO® Airway Inflammation MonitorTufts Medical CenterNot recruiting7 Years65 YearsAll14Phase 3United States
52NCT01016223March 201019 February 2015A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Beclomethasone dipropionate;Drug: placeboPenn State UniversityNot recruiting18 Years65 YearsBoth20Phase 1United States
53NCT02038894December 20096 October 2015Comparing Anesthetic Techniques in Children Having EsophagogastroduodenoscopiesComparison Of Different Anesthetic Techniques In Children Undergoing EsophagogastroduodenoscopiesEosinophilic EsophagitisDrug: Intubated with Sevoflurane (IS);Drug: Intubated with Propofol (IP);Drug: Zofran - no intubation;Drug: PropofolChildren's Hospital Medical Center, CincinnatiNot recruiting1 Year12 YearsBoth179N/AUnited States
54NCT01022970November 200919 February 2015Efficacy and Safety of QAX576 in Patients With Eosinophilic EsophagitisA Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE)Eosinophilic EsophagitisDrug: QAX576 placebo;Drug: QAX576Novartis PharmaceuticalsNot recruiting18 Years50 YearsBoth25Phase 2United States
55NCT00961233October 200919 October 2017Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis.Eosinophilic EsophagitisDrug: inhaled/swallowed budesonide;Drug: viscous/swallowed budesonideUniversity of North Carolina, Chapel HillAstraZenecaNot recruiting18 YearsN/AAll25N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT01040598June 200919 February 2015Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease ModelIdentifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease ModelEosinophilic EsophagitisBiological: OmalizumabO & O Alpan LLCGenentech, Inc.Not recruiting12 Years76 YearsBoth19Phase 1United States
57NCT00762073November 200819 October 2017Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic EsophagitisOral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and AdolescentsEosinophilic Esophagitis (EoE)Drug: budesonide;Drug: placeboShireNot recruiting2 Years18 YearsAll82Phase 2United States
58NCT00880906August 200816 December 2017Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic EsophagitisProspective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic EsophagitisSuspected Eosinophilic EsophagitisProcedure: Esophageal dilation;Drug: Steroid and Proton Pump Inhibitor TherapyVanderbilt UniversityTakedaNot recruiting18 Years75 YearsAll50N/AUnited States
59NCT00635089July 200816 December 2017Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic EsophagitisAn Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002Eosinophilic EsophagitisDrug: reslizumabCeption TherapeuticsCephalonNot recruiting5 YearsN/AAll190Phase 3United States;Canada
60NCT00728481May 200819 October 2017The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic EsophagitisThe Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic EsophagitisEosinophilic Esophagitis;Gastroesophageal Reflux Disease;EE;GERDDrug: Esomeprazole;Drug: BudesonideMayo ClinicAstraZenecaNot recruiting18 Years80 YearsAll51Phase 2/Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61NCT00895817April 200819 October 2017Fluticasone Versus Esomeprazole to Treat Eosinophilic EsophagitisComparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Swallowed fluticasone;Drug: EsomeprazoleWalter Reed Army Medical CenterNot recruiting18 YearsN/AAll42N/AUnited States
62NCT00538434March 200819 October 2017Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsAn Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsEosinophilic EsophagitisBiological: Reslizumab;Other: SalineCeption TherapeuticsNot recruiting5 Years18 YearsAll227Phase 2/Phase 3United States;Canada
63NCT00638456February 200826 August 2019Use of Topical Budesonide in the Treatment of Eosinophilic EsophagitisUse of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical TrialEosinophilic EsophagitisDrug: Budesonide plus Prevacid;Drug: placebo plus PrevacidRanjan DohilMeritage Pharma, Inc.Not recruiting1 YearN/AAll32Phase 2United States
64NCT01404832October 200719 October 2017The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump InhibitorsThe Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump InhibitorsGastroesophageal Reflux Disease;Eosinophilic EsophagitisDrug: Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptomsDallas VA Medical CenterTAP Pharmaceutical Products Inc.Not recruiting18 YearsN/AAll102Phase 4United States
65NCT00511316August 200717 November 2015Trial of Montelukast in Eosinophilic EsophagitisA Randomized Placebo-Controlled Trial of Montelukast in Maintenance Therapy of Asymptomatic Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Montelukast/ Singulair;Drug: PlaceboMayo ClinicMerck Sharp & Dohme Corp.;Merck Sharp & Dohme Corp.Not recruiting18 Years100 YearsBoth41Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT00523354August 200719 February 2015Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic EsophagitisPhase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic EsophagitisEsophagitisDrug: InfliximabSwiss EE Study GroupNot recruiting18 Years70 YearsBothPhase 2Switzerland
67NCT00426283January 200719 October 2017A Study of Flovent in Patients With Eosinophilic EsophagitisA Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Flovent;Other: PlaceboMarc RothenbergNot recruiting3 Years30 YearsAll42Phase 2United States
68NCT00358449September 11, 200616 December 2017Intravenous Mepolizumab In Children With Eosinophilic EsophagitisA Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219)Oesophagitis, EosinophilicDrug: mepolizumabGlaxoSmithKlineNot recruiting2 Years17 YearsAll84Phase 2United States;Australia;Canada;United Kingdom
69EUCTR2005-006074-10-GB15/06/200619 March 2012A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitisA randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitisEosinophilic oesophagitisProduct Name: Mepolizumab
Product Code: SB-240563
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Mepolizumab
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
GlaxoSmithKline Research & Development Ltd.AuthorisedFemale: yes
Male: yes
72United Kingdom
70NCT00271349December 20051 June 2015Budesonide for Eosinophilic EsophagitisBudesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment StudyEosinophilic EsophagitisDrug: BudesonideSwiss EE Study GroupNot recruiting14 Years70 YearsBoth28Phase 2Switzerland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT00123630November 200519 October 2017A Pilot Study of the Treatment of Eosinophilic Esophagitis With OmalizumabA Pilot Study of the Treatment of Eosinophilic Esophagitis With OmalizumabEsophagitisDrug: omalizumab;Drug: PlaceboUniversity of UtahNovartis PharmaceuticalsNot recruiting12 Years60 YearsAll30Phase 2United States
72NCT00275561November 200519 October 2017Topical Steroid Treatment for Eosinophilic EsophagitisA Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Fluticasone;Drug: PlaceboMayo ClinicNot recruiting18 Years60 YearsAll42Phase 2United States
73NCT00148603September 200519 February 2015Montelukast in the Treatment of Duodenal EosinophiliaMontelukast in the Treatment of Duodenal Eosinophilia in Children With Dyspepsia: Effect on Eosinophil Density and Activation in Relation to PharmacokineticsEosinophilic Gastroenteritis;DyspepsiaDrug: montelukastChildren's Mercy Hospital Kansas CityMerck Sharp & Dohme Corp.Not recruiting8 Years17 YearsBoth24N/AUnited States
74NCT00123656August 200419 February 2015Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic EsophagitisComparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic EsophagitisEsophagitisDrug: esomeprazole;Drug: fluticasoneUniversity of UtahAmerican Society for Gastrointestinal EndoscopyNot recruiting18 Years80 YearsBoth30Phase 2United States
75NCT00084097June 2, 200416 December 2017Omalizumab to Treat Eosinophilic GastroenteritisPilot Study of Omalizumab in Eosinophilic GastroenteritisGastroenteritisDrug: OmalizumabNational Institute of Allergy and Infectious Diseases (NIAID)Not recruiting12 Years76 YearsAll30Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT00266578October 200219 February 2015A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic DisordersEffect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled TrialEosinophilic EsophagitisDrug: Fluticasone PropionateMarc RothenbergNot recruiting3 Years30 YearsBoth30Phase 3United States
77NCT00266565December 200116 December 2017Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic SyndromeA Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic SyndromesHypereosinophilic Syndromes;Eosinophilic Gastroenteritis;Churg-Strauss Syndrome;Eosinophilic EsophagitisDrug: MepolizumabChildren's Hospital Medical Center, CincinnatiNot recruiting18 Years65 YearsAll24Phase 1/Phase 2United States
78NCT00017862June 200119 February 2015Anti-Interleukin-5 Antibody to Treat Hypereosinophilic SyndromeA Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional TherapyHypereosinophilic SyndromeDrug: SCH55700National Institute of Allergy and Infectious Diseases (NIAID)Not recruitingN/AN/ABoth10Phase 2United States

先頭へ